Drugs / Buloxibutid
Buloxibutid
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06157580 | Dec 2023 → Oct 2024 | preeclampsia | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 0 | NCT05937841 | Jun 2023 → Aug 2025 overdue | preeclampsia | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 0 | NCT05576155 | Oct 2022 → Feb 2023 | — | Anna Stanhewicz, PhD | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05277922 | Apr → May 2022 | isoproterenol-mediated vasodilatation | Vicore Pharma AB | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06588686 | Dec 2024 → May 2027 expected | idiopathic pulmonary fibrosis | Vicore Pharma AB | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Buloxibutid | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease.” PMID 38344891 ↗ Feb 2024 |
| Known as | C21 | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist, in development for oral treatment of fibrotic lung disease.” PMID 38344891 ↗ Feb 2024 |
| Known as | Compound 21 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05937841 ↗ |
| Known as | T2 agonist compound 21 | ChEMBL registry synonym — accepted as the source's own label CHEMBL189568 ↗ |
| Action | Activate | “Buloxibutid (also known as C21) is a potent and selective angiotensin II type 2 receptor (AT2R) agonist” PMID 38344891 ↗ Feb 2024 |
| Modality | Small molecule | — CHEMBL189568 ↗ |
| Route | Other | “through local intra-arterial infusions for 5 min/dose” NCT05277922 ↗ |